Book cover for Pharmacology and the Nursing Process

Pharmacology and the Nursing Process

Linda Lane Lilley, Shelly Rainforth Collins, Julie S. Snyder

ISBN #9780323087896

7th Edition

394 Questions

Group icon
2,697 Students Helped

Homework Questions

Right arrow
Summary
Learning Objectives
Key Concepts
Example Problems
Explanations
Common Mistakes

Summary

Chapter 30 on Pituitary Drugs combines key aspects of endocrinology and pharmacology, focusing on the hypothalamic-pituitary axis and its fundamental role in physiological regulation. The chapter emphasizes various critical drug classes—including MAO-B inhibitors, alpha blockers, beta blockers, and cytotoxic agents—highlighting their mechanisms, kinetics, clinical applications, and the importance of understanding drug interactions for effective therapy.

Learning Objectives

1

Understand the structure and function of the neuroendocrine system, focusing on the hypothalamic-pituitary axis.

2

Explain the pharmacodynamics and pharmacokinetics of key pituitary drugs and related drug classes.

3

Analyze the mechanisms of action and clinical applications of MAO-B inhibitors, alpha blockers, beta blockers, alkylating agents, and cytotoxic agents.

4

Evaluate the integration of endocrinology and pharmacology in safe and effective therapeutic management.

Key Concepts

CONCEPT

DEFINITION

Neuroendocrine System

The system that integrates the nervous and endocrine systems to regulate physiological functions.

Hypothalamic-Pituitary Axis

A regulatory system involving the hypothalamus and pituitary gland, crucial for hormone production and feedback control.

MAO-B Inhibitors

Drugs that inhibit the monoamine oxidase B enzyme, used mainly in the treatment of Parkinson’s disease to enhance dopamine levels.

Alpha Blockers

Medications that block alpha adrenergic receptors, employed to manage hypertension and benign prostatic hyperplasia (BPH) by relaxing smooth muscle.

Beta Blockers

Drugs that inhibit beta-adrenergic receptors in cardiac tissue, reducing heart rate and myocardial contractility to alleviate cardiac stress.

Alkylating Agents

A class of cytotoxic drugs that work by attaching alkyl groups to DNA, used in chemotherapy to treat cancer.

Cytotoxic Agents

Drugs that kill or damage cells, often used in cancer treatment to target rapidly dividing cells.

Pharmacokinetics

The branch of pharmacology concerned with the absorption, distribution, metabolism, and excretion of drugs.

Drug Interactions

The effects that may occur when one drug influences the activity of another, affecting efficacy and safety.

Example Problems

Example 1

A patient is experiencing severe diarrhea, flushing, and lifethreatening hypotension associated with carcinoid crisis. The nurse will prepare to administer which drug? a octreotide (Sandostatin) b vasopressin (Pitressin) c somatropin (Humatrope) d cosyntropin (Cortrosyn)

Example 2

A patient is suspected of having adrenocortical insufficiency. The nurse expects to administer which drug to aid in the diagnosis of this condition? a octreotide (Sandostatin) b vasopressin (Pitressin) $c$ somatropin (Humatrope) d cosyntropin (Cortrosyn)

Example 3

The nurse is reviewing the medication list for a patient who will be starting therapy with somatropin. Which type of drug would raise a concern that needs to be addressed before the patient starts the somatropin? a Nonsteroidal antiinflammatory drug for arthritis b Antidepressant drug c Penicillin d Glucocorticoid

Example 4

A patient who is about to be given octreotide is also taking a diuretic, IV heparin, ciprofloxacin (Cipro), and an opioid as needed for pain. The nurse will monitor for what possible interaction? a Hypokalemia due to an interaction with the diuretic b Decreased anticoagulation due to an interaction with the heparin c Prolongation of the QT interval due to an interaction with ciprofloxacin d Increased sedation if the opioid is given

Example 5

When monitoring for the therapeutic effects of intranasal desmopressin (DDAVP) in a patient who has diabetes insipidus, which assessment finding will the nurse look for as an indication that the medication therapy is successful? a Increased insulin levels b Decreased diarrhea c Improved nasal patency d Decreased thirst
Scroll left
Scroll right

Step-by-Step Explanations

QUESTION

How does the hypothalamic-pituitary axis regulate physiological processes?

STEP-BY-STEP ANSWER:

Step 1: Identify the hypothalamus as the control center that produces releasing hormones.
Step 2: Understand that these releasing hormones activate the pituitary gland.
Step 3: Recognize that the pituitary secretes tropic hormones targeting peripheral endocrine glands.
Step 4: Outline the feedback mechanisms that balance hormone levels throughout the system.
Final Answer: The hypothalamic-pituitary axis maintains homeostasis through a series of hormonal signals and feedback loops.

Hypothalamic-Pituitary Axis

QUESTION

What is the mechanism of action of MAO-B inhibitors in managing Parkinson’s disease?

STEP-BY-STEP ANSWER:

Step 1: Recognize that MAO-B inhibitors block the monoamine oxidase-B enzyme.
Step 2: Understand that this inhibition prevents the breakdown of dopamine in the brain.
Step 3: Note that the increased dopamine levels help alleviate motor symptoms in Parkinson’s disease.
Final Answer: MAO-B inhibitors work by inhibiting dopamine degradation, thereby enhancing dopamine availability and improving motor function in Parkinson’s patients.

MAO-B Inhibitors

QUESTION

How do beta blockers reduce cardiac stress?

STEP-BY-STEP ANSWER:

Step 1: Identify beta adrenergic receptors located in the heart.
Step 2: Explain that beta blockers prevent adrenaline from binding to these receptors.
Step 3: Describe how this blockade reduces heart rate and myocardial contractility.
Step 4: Conclude that the overall decrease in cardiac workload leads to reduced stress on the heart.
Final Answer: Beta blockers mitigate cardiac stress by blocking beta adrenergic receptors, thereby decreasing the effects of adrenaline on the heart.

Beta Blockers

Scroll left
Scroll right

Common Mistakes

  • Confusing the functions of the hypothalamus with those of the pituitary gland.
  • Overlooking the importance of feedback mechanisms in the hypothalamic-pituitary axis.
  • Misinterpreting the specific roles or side effects of drug classes such as MAO-B inhibitors or beta blockers.
  • Neglecting the influence of pharmacokinetics on the effectiveness and safety of therapeutic drugs.
  • Failing to recognize potential drug interactions when multiple drug classes are combined in treatment.